An Alternative In Vitro Model Of Neurodegeneration In Ftld-U With Pgrn Mutation

michael a gitcho,odity mukherjee,jun wang,sumi chakraverty,jeffrey strider,joanne norton,alison goate,nigel j cairns

DOI: https://doi.org/10.1096/fasebj.22.1_supplement.58.7

2008-01-01

Abstract:Recently, the gene for familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions (FTLD‐U) linked to chromosome 17 was cloned. In the present study, 42 unrelated patients from the Washington University Alzheimer's Disease Research Center (WUADRC) with clinically diagnosed FTLD and/or neuropathologically characterized cases of FTLD‐U with or without MND were screened for mutations in PGRN . Bidirectional sequencing was performed for mutational screening. Mechanistically, most mutations in PGRN described thus far have been reported to display a haploinsufficiency through nonsense mediated decay (NMD). We describe a novel missense mutation in exon 1 (c.4068 C>A) introducing a charged amino acid in the hydrophobic core of the signal peptide at residue 9 (A9D) which displayed no significant difference in the total postmortem brain PGRN mRNA between cases and controls. In SHSY‐5Y neuroblastoma cells overexpressed with mutant or wild‐type PGRN , subcellular fractionation, biochemistry, and confocal microscopy indicate that mutant protein is expressed, but is not processed, through the ER for secretion, and appears to be misslocalized in the cytosol possibly resulting in a functional haploinsufficiency. This defect in trafficking results in a decrease in cell viability: an alternative in vitro model of FTLD‐U with PGRN mutation neurodegeneration. Support for this work was provided by grants from the National Institute on Aging of the National Institutes of Health (P01‐AG03991, P50‐AG05681) and the Buchanan Fund.